Insulet Delivers 26% Revenue Growth and Raises 2017 Guidance; Stock Pumps Up 7%
Insulet (NASDAQ: PODD) reported second-quarter 2017 earnings after the market closed on Thursday.
The drug-delivery company, which is a leader in tubeless insulin pump technology with its Omnipod Insulin Management System, delivered revenue growth of 26% -- which exceeded its guidance -- while its loss per share widened, driven by increased research-and-development expenses and interest expenses. The company also raised its revenue guidance for 2017.
The market liked the results, sending Insulet shares to a closing gain of 7.1% on Friday. The stock has gained 51.5% for the one-year period through Friday, outpacing the S&P 500's total return of 16.9%.
Source: Fool.com
Insulet Corp. Aktie
180,05 €
-1,89 %
Eine klare Neigung zu Buy-Einschätzungen bei Insulet Corp., ohne Sell-Einschätzungen.
Ein positives Kurspotenzial für Insulet Corp. ist gegeben, mit einem Kursziel von 216 € über dem aktuellen Kurs von 180.05 €.
